Skip to contentI
IGC Pharma, Inc.
I
IGCIGC Pharma, Inc. Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$122.00K$122.00Kderived+50.6% vs Q4 2021 Net Income-$6.50M-$6.50MderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$68,000+151.9% Operating Incomederived-$6,501,000N/M Margins · derivedGross margin55.7%+22.4 pt vs Q4 2021
Operating margin-5328.7%−1883.0 pt vs Q4 2021
Net margin-5330.3%−1689.6 pt vs Q4 2021
ended Mar 31, 2022 · filed Jun 23, 2022 · 84 d after period end